Finerenone in Type 1 Diabetes and Chronic Kidney Disease
In adults with type 1 diabetes and CKD, finerenone resulted in a significantly greater decrease in the urinary albumin-to-creatinine ratio than placebo. (Funded by Bayer; FINE-ONE ClinicalTrials.gov number, NCT05901831.).
Authors
- John M. Russell
- Niels Jongs (ORCID: https://orcid.org/0000-0002-0882-3656)
- Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
- Patrick Schloemer (ORCID: https://orcid.org/0009-0004-7787-5662)
- Robert Lawatscheck (ORCID: https://orcid.org/0009-0003-4253-6313)
- Chantal Mathieu (ORCID: https://orcid.org/0000-0002-6099-2406)
- Peter Rossing
- Markus F. Scheerer
- Helen M Colhoun
- David Z.I. Cherney
- Janet B. McGill
- Jay S. Skyler
- Sylvia Rosas
- Meike Brinker
- Per-Henrik Groop
- Katherine R. Tuttle
- Richard E. Pratley
- Andreas L. Birkenfeld
- Linong Ji
Institutions
- University of Copenhagen (DK)
- Joslin Diabetes Center (US)
- University Health Network (CA)
- University Medical Center Groningen (NL)
- University of Helsinki (FI)
- Steno Diabetes Centers (DK)
- University of Miami (US)
- University of Groningen (NL)
- Peking University (CN)
- Washington University in St. Louis (US)
- Helsinki University Hospital (FI)
- Inland Northwest Health Services (US)
- Edinburgh Cancer Research (GB)
- UNSW Sydney (AU)
- Peking University People's Hospital (CN)
- Climate Analytics (DE)
- Translational Research Institute for Metabolism and Diabetes (US)
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- Bayer (United Kingdom) (GB)
- Heinrich Heine University Düsseldorf (DE)
- Bayer (Germany) (DE)
- University of Tübingen (DE)
- KU Leuven (BE)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1056/nejmoa2512854
- Citations
- 2
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 61.46